| CAS NO: | 125317-39-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 1079.11 |
|---|---|
| Formula | C45H54N4O8.2C4H6O6 |
| CAS No. | 125317-39-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (92.7 mM) |
| Water: 100 mg/mL (92.7 mM) | |
| Ethanol: 100 mg/mL (92.7 mM) | |
| Other info | Chemical Name: methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis((2R,3R)-2,3-dihydroxysuccinate) InChi Key: CILBMBUYJCWATM-PYGJLNRPSA-N InChi Code: InChI=1S/C45H54N4O8.2C4H6O6/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7;2*5-1(3(7)8)2(6)4(9)10/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3;2*1-2,5-6H,(H,7,8)(H,9,10)/t28-,37-,38+,39+,42+,43+,44-,45-;2*1-,2-/m011/s1 SMILES Code: O=C(OC)[C@@]1([C@@]2(N(C3=C([C@@]24CCN5CC=C[C@@](CC)([C@H]1OC(C)=O)[C@@]45[H])C=C(C(OC)=C3)[C@]6(C[C@]7([H])C=C(CN(CC8=C6NC9=C8C=CC=C9)C7)CC)C(OC)=O)C)[H])O.O=C([C@@H]([C@H](C(O)=O)O)O)O.O=C([C@@H]([C@H](C(O)=O)O)O)O |
| Synonyms | KW2307, Nor-5'-anhydrovinblastine ditartrate, vinorelbine tartrate, KW-2307, KW 2307, Navelbine, Biovelbin, Eunades |
| In Vitro | In vitro activity: Vinorelbine inhibits microtubule assembly by inducing tubulin aggregation into spirals and paracrystals. Vinorelbine shows potent antiproliferative activity against a series of tumor cells, including human melanoma, non-small-cell lung cancer, breast cancer, etc. |
|---|---|
| In Vivo | In vivo, Vinorelbine also shows antitumour activity against a series of subcutaneously-implanted human tumour xenografts. |
| Animal model | Bladder (BXF1299), pancreas (PAXF546), kidney (RXF944LX), colon (DLD-1, HT-29, TC37), central nervous system (SF-295), small cell lung (NCI-H69) and prostate (PC-3) xenografts. |
| Formulation & Dosage | Dissolved in Sterile 0.9% sodium chloride solution; 10 mg/kg; i.p. injection |
| References | Semin Oncol. 1989 Apr;16(2 Suppl 4):9-14; Eur J Cancer. 1999 Mar;35(3):512-20. |
m.cnreagent.com